Patent: 8,895,033
Summary for Patent: 8,895,033
| Title: | Sustained release formulations using non-aqueous carriers | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Houchin; Mary L. (Rockville, MD), Lee; Robin H. (San Diego, CA), Qi; Hong (San Diego, CA), Oehrtman; Greg (San Diego, CA), Jennings; Robert N. (San Diego, CA), Coleman; Scott H. (San Diego, CA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Amylin Pharmaceuticals, LLC (San Diego, CA) AstraZeneca Pharmaceuticals LP (Wilmington, DE) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | 13/060,225 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Claims: | see list of patent claims | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims summary: | United States Patent 8,895,033: Claim Scope, Patent Strength, Exclusivity and Competitive LandscapeUnited States Patent 8,895,033 protects a ready-to-use injectable suspension containing biodegradable polymer microspheres dispersed in a medium-chain triglyceride carrier. Its broadest independent claim requires four core elements: a pre-mixed injectable product, a nonaqueous triglyceride carrier, biodegradable polymer microspheres containing an active ingredient, and a narrowly defined C6-C12 fatty-acid profile. The patent also contains narrower claim coverage for PLGA microspheres, sucrose, exenatide, a 1:1 lactide:glycolide ratio, therapeutic methods and injection-device kits. The patent is most relevant to long-acting injectable formulations of exenatide and other peptide or small-molecule APIs. It does not automatically cover every exenatide microsphere product. A competing product must satisfy the carrier composition, microsphere and pre-mixing limitations to fall within the independent formulation claims. What does United States Patent 8,895,033 protect?The patent protects a formulation architecture rather than exenatide as a molecule. The central combination is:
The fatty-acid profile is a major claim boundary. It effectively describes a medium-chain triglyceride system dominated by octanoic and decanoic acid residues. A carrier outside the claimed C8/C10 ranges could avoid literal infringement even if the product otherwise uses PLGA microspheres and exenatide. How are the claims structured?Claims 1-8: broad formulation claimsClaim 1 is the primary composition claim. It covers a suspension of biodegradable microspheres in a specified triglyceride carrier. Claim 2 adds a pharmaceutically acceptable excipient. Claim 3 limits the excipient to a sugar or sugar alcohol and adds an antioxidant or preservative. Claim 4 lists specific excipients, including sucrose, trehalose, mannitol, sorbitol, parabens, tocopherol, ascorbate and related materials. Claim 5 excludes a gel-forming agent. This negative limitation may be commercially significant because it distinguishes a free-flowing suspension from in situ gel systems or viscous depot formulations. Claim 6 contains a broad polymer Markush group. It includes:
Claim 7 covers a wide API class. The list includes GLP-1 receptor agonists, exenatide, pramlintide, insulin, glucagon-related agents, metreleptin, salicylates, minocycline and small-molecule compounds. Claim 8 limits microsphere concentration to 10-500 mg/mL, or 20-200 mg/mL. The alternative ranges provide fallback positions but also create measurable design-around opportunities. Claims 9-10: method-of-use protectionClaim 9 covers administration of the claim 1 formulation for metabolic and gastrointestinal indications, including:
Claim 10 adds coadministration with metformin, a sulfonylurea or a thiazolidinedione. These method claims are narrower than a conventional exenatide method claim because they require use of the specific formulation in claim 1. They should not be treated as independent protection for exenatide therapy generally. Claims 11-12: kit and device claimsClaims 11 and 12 cover a container holding the formulation with instructions for use. The container may be a:
These claims extend the patent beyond bulk formulation manufacture. A commercial product could face separate infringement exposure from its packaging or delivery system if the formulation and container limitations are satisfied. Claims 13-18: exenatide and PLGA fallback claimsClaim 13 is the most commercially specific formulation claim. It requires:
Claims 14-18 create narrower combinations involving PLGA, exenatide, approximately 5 wt% exenatide and sucrose. The claim language creates a strong technical fingerprint. A product using exenatide-loaded 1:1 PLGA microspheres in a medium-chain triglyceride carrier with approximately 2% sucrose and 5% peptide loading would be substantially closer to the patent than a conventional aqueous exenatide microsphere suspension. How strong is the patent estate for US 8,895,033?The patent has meaningful breadth at the platform level but its enforceability depends heavily on claim construction and proof of the carrier composition.
Likely validity pressure pointsThe principal validity issues are predictable for this type of formulation patent. First, the polymer Markush language is extensive. A challenger could argue that the specification does not enable the full range of listed polymers, APIs and formulation combinations without undue experimentation. The risk is greatest where the claims cover polymer classes that have materially different degradation, loading and release characteristics. Second, prior-art references may disclose biodegradable microspheres in triglyceride vehicles, or exenatide microspheres in injectable carriers. The patent's strongest novelty position is likely the specific combination of a pre-mixed suspension and the defined C8/C10 fatty-acid profile. Third, the claims use approximate terms such as "about 2 wt%" and "about 5 wt%." Courts generally interpret "about" in context, based on the specification, prosecution history and technical variability. Those terms create flexibility but can also generate litigation over analytical tolerances. Fourth, claim 13 appears to contain unusual dependency and drafting structure. Claims 14-18 refer back to earlier claims while restating elements associated with the narrower exenatide formulation. The prosecution history would be important in determining whether those claims were amended, corrected or narrowed during examination. When does US 8,895,033 lose exclusivity?The patent issued on December 2, 2014. Its effective patent term is generally measured as 20 years from the earliest effective nonprovisional or PCT filing date under 35 U.S.C. §154. Public patent records associate the application with a 2009 international filing and an earlier 2008 priority date. On that basis, the nominal expiration is in 2029, subject to patent-term adjustment, patent-term extension and any terminal disclaimer recorded by the USPTO.
The grant date does not determine expiration. A later continuation, divisional or related patent may expire on a different date, but a later-filed continuation does not ordinarily receive a fresh 20-year term. What is the Orange Book status of US 8,895,033?US 8,895,033 should not be assumed to be an Orange Book patent merely because it claims an injectable drug formulation. The FDA Orange Book lists patents submitted by an NDA holder for an approved drug product, subject to the statutory and regulatory requirements governing drug substance, drug product and method-of-use patents. A patent directed to a platform formulation may be eligible for listing only if it appropriately reads on the approved drug product or an approved use. The approved Bydureon products historically used exenatide encapsulated in PLGA microspheres, but the commercial presentation involved reconstitution with an aqueous diluent before administration. The FDA-approved product description is therefore materially different from the claimed pre-mixed nonaqueous triglyceride suspension.[2] The practical conclusion is:
The FDA Orange Book should be checked by patent number and product NDA for current listing status. Patent listing status can change through delisting, product withdrawal or regulatory corrections.[1] What patent landscape surrounds exenatide microsphere formulations?The relevant landscape has three layers. Exenatide molecule and peptide patentsThe exenatide molecule and its therapeutic use are distinct from the formulation claims in US 8,895,033. Older exenatide patents have largely reached the end of their ordinary terms or are no longer the principal barrier to entry. Current risk is more likely to arise from formulation, device, manufacturing and method-of-use patents. PLGA microsphere patentsPLGA depot patents often claim:
US 8,895,033 differs from many conventional depot patents because the principal vehicle is a nonaqueous triglyceride carrier and the formulation is pre-mixed before administration. Approved exenatide productsBydureon and Bydureon BCise are the most relevant commercial comparators. Their product technology is based on extended-release exenatide microspheres, but the approved products are supplied with or in a system involving an aqueous diluent and reconstitution or suspension before injection.[2,3]
Which companies are challenging or licensing around the patent?No publicly established Paragraph IV challenge or settlement specific to US 8,895,033 is identified in the supplied record. The absence of a known case does not establish that the patent is unchallenged. A Paragraph IV dispute would generally require an ANDA applicant to identify the patent in its certification and the NDA holder to bring suit within the statutory period. The more probable commercial risk is not a direct exenatide generic challenge. It is development of an alternative long-acting injectable using:
A biosimilar analysis is generally inapposite. Exenatide is a chemically synthesized peptide drug, not a biologic approved through the traditional biologics pathway. The principal competitive pathway is therefore generic or hybrid drug development, not a conventional biosimilar pathway.[4] What generic entry risks exist?A generic or follow-on developer faces several distinct risks. Literal infringement riskThe highest risk arises when all measurable elements are present:
Equivalents riskA product outside a numerical range could still create a doctrine-of-equivalents dispute. The risk is lower where the fatty-acid distribution materially changes suspension stability, injection performance or release behavior. Prosecution-history estoppel could restrict the patentee if the ranges were added to overcome prior art. Regulatory substitution riskA product that uses a different presentation may avoid this patent but still require separate FDA work on:
Avoiding the patent does not eliminate development risk. It shifts risk to formulation, manufacturing and regulatory validation. What manufacturing and IP barriers matter most?The patent claims the final formulation, not every process needed to produce it. A commercial entrant would still need to control:
The carrier limitation is particularly important because triglyceride excipients may vary by supplier, grade and analytical method. Fatty-acid composition should be measured against the total fatty-acid content of the triglycerides, as the claim requires. A label declaration alone may not resolve infringement; batch-specific composition and supplier specifications may be relevant. How does US 8,895,033 compare with typical depot formulation patents?
Key Takeaways
FAQsDoes US 8,895,033 cover all long-acting exenatide injections?No. The independent formulation claim requires a pre-mixed nonaqueous triglyceride carrier with a specified fatty-acid profile and biodegradable microspheres. Can an aqueous exenatide microsphere product infringe this patent?Usually not literally, because claim 1 requires a pharmaceutically acceptable nonaqueous carrier comprising one or more triglycerides. Other claims or related patents could still be relevant. Is the 1:1 PLGA ratio required for every claim?No. It is required by the narrower claims directed to that specific PLGA composition. Claim 1 and several other claims use broader polymer language. Does the patent protect a pen injector by itself?No. The kit claims require a container holding the claimed formulation and instructions for use. A pen containing a different formulation would not satisfy those limitations. Is a follow-on exenatide product a biosimilar?Generally no. Exenatide products are typically evaluated through the generic or hybrid drug framework rather than the conventional biosimilar pathway. References
More… ↓ |
Details for Patent 8,895,033
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Chiesi Farmaceutici S.p.a. | MYALEPT | metreleptin | For Injection | 125390 | February 24, 2014 | ⤷ Start Trial | 2029-09-04 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
